FDA Officials Discuss Sentinel’s Challenges

Drug GMP Report
A A
The biggest challenge for the FDA’s 10-year-old Sentinel program for post-market safety monitoring of medical products is having to deal with a wide range of partners and data sources, according to CDER Deputy Director Robert Ball.

To View This Article:

Login

Subscribe To Drug GMP Report